Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
US10280468B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2015 |
| Grant date | May 7, 2019 |
| Priority date | — |
| Expiry date | Feb 9, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.